

8 DECEMBER 2025

INDEPENDENT DIRECTOR DETERMINATION – NZX LISTING RULE 2.6

Pacific Edge Limited – Independent Director Determination

As required by NZX Listing Rule 2.6.1 and 2.6.2, the Board of Pacific Edge Limited has determined that Simon Richard Flood is an Independent Director for the purposes of the NZX Listing Rules.

Background

Simon Richard Flood was appointed to the Board on 4 December 2025. The Board has considered the range of factors outlined in the NZX Corporate Governance Code (including any interests, relationships, or positions that could reasonably influence the Director's ability to act independently).

In the Board's judgment, there are no relationships or interests that materially compromise or could reasonably be perceived to compromise the Director's independence. Accordingly, Simon Richard Flood is classified as an Independent Director under the NZX Listing Rules.

Contact for Further Information:

Grant Gibson
Chief Financial Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.